AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza, jointly developed with US-based Merck & Co, was approved last year by the US Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations.
Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
&uuid=(email))